A5086766952- HIV, Drug Use, Sexual Risk
- Hepatitis C virus research
- Hepatitis B Virus Studies
- HIV/AIDS Research and Interventions
- Liver Disease Diagnosis and Treatment
- Collaborative Teaching and Inclusion
- Alcohol Consumption and Health Effects
- Cytomegalovirus and herpesvirus research
- Vascular Procedures and Complications
- Opioid Use Disorder Treatment
- Educational Practices and Policies
- Innovative Approaches in Technology and Social Development
- Central Venous Catheters and Hemodialysis
- Drug-Induced Hepatotoxicity and Protection
- Innovation and Knowledge Management
- Venous Thromboembolism Diagnosis and Management
- HIV-related health complications and treatments
The University of Texas Medical Branch at Galveston
2024
Burnet Institute
2019-2023
Alexandra Hospital
2023
Australian Centre for HIV and Hepatitis Virology Research
2018
La Trobe University
2018
Arizona State University
2002
Abstract Whilst the testing and treatment of people who inject drugs (PWID) in Australia is a priority for local hepatitis C (HCV) elimination efforts, perceived stigma related to injecting drug use (IDU) has been identified as major barrier PWID engaging health services. We used data from EC Experience cohort study explore associations between IDU‐related number different services accessed by Melbourne, Australia. Data baseline questionnaire were used. Primary outcome was self‐reported...
Abstract Objective s Improved life expectancy has led to an ageing population of people living with HIV in most countries. Research on among predominantly focused physical and health‐related quality rather than multidimensional life. We measured older Australia identified opportunities guide the development implementation appropriate interventions. Methods In a national health wellbeing survey Australian HIV, participants aged ≥50 years completed additional questions relevant ageing. Quality...
MH and AP receive investigator-initiated research funding support from Gilead Sciences, Abbvie BMS. The authors confirm that the data supporting findings of this study are available within article. Specific not included in formal analysis on request corresponding author (IE). Some will be made publicly due to potential compromise privacy participating sites participants.
Objectives Direct-acting antivirals provide an opportunity to eliminate hepatitis C virus (HCV) as a public health threat in Australia, yet barriers care remain. In this study, we use baseline data from longitudinal cohort of people who inject drugs understand differences participant characteristics and explore experiences stigma, service utilisation literacy between three cascade groups. Design Cross-sectional. Setting Community private primary healthcare services Melbourne, Australia....
Abstract Recent guidance from the World Health Organization strongly recommended hepatitis C virus (HCV) self‐testing. We implemented Vend‐C pilot study to explore effectiveness and feasibility of distributing rapid HCV antibody self‐test kits people who inject drugs via needle/syringe dispensing machines (SDMs). Over a 51‐day period between August September 2022, we distributed two SDMs. During period, 63 were dispensed, averaging 1.2 per day. Our access methods for evaluation...
Introduction The advent of direct acting antiviral therapy for hepatitis C virus (HCV) means the elimination HCV is possible but requires sustained effort to achieve. Between 2016 and 2019, 44% those living with were treated in Australia. However, treatment uptake has declined significantly. In Australia, people who inject drugs (PWID) are population most at risk acquisition. Eliminating Australia will require nuanced understanding barriers experienced by PWID tailored interventions address...
PMD has received investigator-driven research funding from Gilead Sciences for work on hepatitis C unrelated to this work. served as an unpaid member of Advisory Board intranasal naloxone product.